Polycystic Ovarian Syndrome Treatment Market 2024 Analysis By Size, Share, Growth, Trends Up To 2033 | Bristol-Myer Squibb Co, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi SA

"The polycystic ovarian syndrome treatment market size has grown strongly in recent years. It will grow from $4.49 billion in 2023 to $4.74 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increased awareness, advances in medical technology, lifestyle changes, pharmaceutical innovations, government initiatives.

The polycystic ovarian syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $6.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to personalized medicine, telemedicine and remote monitoring, research and development, rising prevalence, supportive regulatory environment. Major trends in the forecast period include holistic approach, patient-centered care, digital health solutions, multidisciplinary care, patient education.

Market Overview -
Polycystic ovarian syndrome is a disorder in which hormones are out of control for females and they have male hormones that are higher than normal, which causes them to skip menstrual periods and makes pregnancy more difficult for them.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=2827&type=smp

Elevated Incidence Of Genetic And Hormonal Disorders Fuels Growth In The Polycystic Ovarian Syndrome (PCOS) Treatment Market
The global rise in genetic and hormonal disorders is a key factor driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. PCOS is a prevalent hormonal disorder among premenopausal women worldwide, with reproductive, endocrine, and metabolic abnormalities. The PCOS prevalence ranges from 2.2% to 26% globally and is highly variable. In China, the figures range between 2% to 7.5% and 6.3% in Sri Lanka, 9.13% in south India and 22.5% in Maharashtra. The rise in genetic and hormonal disorders globally is expected to increase the growth of the polycystic ovarian syndrome treatment market.

Competitive Landscape -
Major companies operating in the polycystic ovarian syndrome treatment market include Bristol-Myer Squibb Co, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi SA, AstraZeneca PLC, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott Laboratories, Addex Therapeutics Ltd., BIOCAD, Allergan plc., Johnson and Johnson, Ferring Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Organon & Co, Forendo Pharma Ltd., GlaxoSmithKline plc, AbbVie Inc., Eli Lilly and Company, Mylan NV, Lupin Pharmaceuticals Inc., HRA Pharma SAS, CooperSurgical Inc., TherapeuticsMD Inc., Agile Therapeutics Inc., OvaScience Inc., Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Glenmark Pharmaceuticals Limited

Laparoscopic Ovarian Drilling A Prominent Trend In Polycystic Ovarian Syndrome (PCOS) Treatment Advancement
Laparoscopic ovarian drilling is a major trend driving the growth of the polycystic ovarian syndrome treatment market. Laparoscopic ovarian drilling is a surgical treatment performed by doctors in critical conditions that can cause ovulation in women with (PCOS). Ovarian drilling is often used by women with PCOS who often do not ovulate despite having attempted weight loss and the use of fertility drugs. According to a 2021 study published on Taylor and Francis online, an American open access journal, the efficacy of ovarian drilling was variable in different literature. Ovulation and pregnancy rates were found to be 30%-90% and 13%-80% respectively.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/polycystic-ovarian-syndrome-treatment-global-market-report

Key Segments -
The polycystic ovarian syndrome treatment market covered in this report is segmented -
1) By Drug Type: Oral Contraceptives, Ornithine Decarboxylase Inhibitors, Insulin-Sensitizing Agents, Anti-Depressants, Diuretics, Aromatase Inhibitors
2) By Surgery Type: Ovarian Wedge Resection, Laparoscopic Ovarian Drilling
3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Gynecology Centers, Feminist Health Centers

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.